ERBB2 and breast carcinoma: However, there remains a great deal of uncertainty about the distribution of ER and HER2 expression in breast cancer in Sub-Saharan Africa due to a combination of variable quality control for biomarker testing and a high level of population diversity in the region [16, 17].